Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-04-28 | Mr. Raab holds a B.A. from DePauw University. |
| 2018-04-27 | Mr. Raab has significant experience in drug development and commercialization of products in the rare diseases, cardio renal and GI diseases. |
| 2019-04-29 | Mr. Raab holds a B.A. from DePauw University. |
| 2020-04-24 | Mr. Raab holds a B.A. from DePauw University. |
| 2021-04-27 | Michael G. Raab has served as a member of the Board of Directors since 2004 and as Lead Independent Director since September 2018. Mr. Raab has served as President and Chief Executive Officer of Ardelyx, Inc. (NASDAQ: ARDX) since March 2009. Mr. Raab previously served as a partner of New Enterprise Associates (“NEA”) from June 2002 until December 2008, with a focus on healthcare investing. From 1999 to 2002, he was Senior Vice President, Therapeutics and General Manager, Renagel® at Genzyme Corporation. Mr. Raab currently serves as a member of the Board of Directors of Ardelyx, Inc. Mr. Raab serves as Chairman of Tempest Therapeutics, a San Francisco based clinical stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor pathways. He also serves on the Emerging Companies and Health Section Governing Boards of the Biotechnology Innovation Organization. Mr. Raab holds a B.A. from DePauw University. |
| 2022-04-26 | Mr. Raab holds a B.A. from DePauw University. |
| 2023-04-26 | Mr. Raab holds a B.A. from DePauw University. |
| 2024-04-24 | Mr. Raab holds a B.A. from DePauw University. |
Data sourced from SEC filings. Last updated: 2026-02-03